Provided by Tiger Trade Technology Pte. Ltd.

Corcept Therapeutics

122.25
+1.200.99%
Post-market: 122.250.00000.00%19:58 EDT
Volume:656.44K
Turnover:80.15M
Market Cap:13.22B
PE:269.48
High:123.44
Open:121.48
Low:120.56
Close:121.05
52wk High:123.44
52wk Low:28.66
Shares:108.10M
Float Shares:96.44M
Volume Ratio:0.88
T/O Rate:0.68%
Dividend:- -
Dividend Rate:- -
EPS(TTM):0.4537
EPS(LYR):0.8200
ROE:8.23%
ROA:0.47%
PB:18.72
PE(LYR):149.09

Loading ...

Corcept Therapeutics - Resubmission Includes Additional Analyses; Expects Six-Month FDA Review

THOMSON REUTERS
·
Jun 18

Corcept Therapeutics (CORT) Valuation After New Korlym CATALYST And MOMENTUM Trial Data

Simply Wall St.
·
Jun 10

Corcept announces presentation of new data from Catalyst, Momentum trials

TIPRANKS
·
Jun 08

Lifyorli Survival Data and DOJ Update Might Change The Case For Investing In Corcept Therapeutics (CORT)

Simply Wall St.
·
Jun 07

Corcept Chief Development Officer William Guyer disposes of 20,000 common shares for $1.41 million

Reuters
·
Jun 05

Corcept Endocrinology President Sean Maduck disposes of Corcept Therapeutics shares worth $1.75 million

Reuters
·
Jun 04

Corcept CFO Atabak Mokari sells 40,000 shares for USD 2.8 million

Reuters
·
Jun 04

Corcept Therapeutics - DOJ, California Department of Insurance, and Plaintiff States Decline to Intervene in Lawsuit - SEC Filing

THOMSON REUTERS
·
Jun 03

Corcept Therapeutics Inc: Intends to Defend Against All of Relator's Claims

THOMSON REUTERS
·
Jun 03

Corcept Therapeutics - DOJ Previously Issued Records Subpoena to Corcept in Nov 2021 Regarding Korlym Sales and Promotion - SEC Filing

THOMSON REUTERS
·
Jun 03

Corcept Therapeutics - Relator Serves Corcept With Amended Complaint on June 2, 2026 - SEC Filing

THOMSON REUTERS
·
Jun 03

Corcept says DOJ declines to intervene in Korlym-related qui tam lawsuit

Reuters
·
Jun 03

Wall Street Analysts Are Bullish on Top Healthcare Picks

TIPRANKS
·
Jun 01

Corcept Chief Accounting & Technology Officer Joseph Douglas Lyon sells 5,000 shares for $325,000

Reuters
·
May 30

Corcept Endocrinology President Sean Maduck sells USD 4.92 million Corcept Therapeutics shares

Reuters
·
May 30

Corcept Therapeutics holds annual shareholder meeting, backs amended 2024 incentive plan

Reuters
·
May 29

Corcept Therapeutics Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
May 28

U.S. RESEARCH ROUNDUP-Salesforce, Snowflake, Zscaler

Reuters
·
May 28

Corcept Therapeutics Inc : Canaccord Genuity Raises Target Price to $135 From $110

THOMSON REUTERS
·
May 28

Corcept Therapeutics to resubmit NDA to U.S. FDA for relacorilant

TIPRANKS
·
May 27